Oncolytics Biotech provides enrollment update on multi-indication phase 1/2 gastrointestinal cancer trial at 2022 ASCO-GI symposium
Summary : Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins Company moving to full enrollment pending independent safety review…